KURA News and Press, Kura Oncology Inc. From 12/08/19

– Tipifarnib demonstrates robust and durable activity as a monotherapy in advanced AITL, an aggressive form of T-cell lymphoma – – Enhanced activity (40% CR rate, 70% ORR) observed in AITL patients with KIR mutations, a CXCL pathway-associated biomarker – &#...

SAN DIEGO, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Off...

Kura Oncology ( KURA ) is a biotech that should be on everyone's radar. That's because it has an upcoming catalyst that could be a game changer. It has already reported results from its phase 2 study using Tipifarnib to treat patients with relapsed/refractory Peripheral T-cell lymphoma ((PTC...

SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Off...

Kura Oncology, Inc. (KURA) Q3 2019 Earnings Conference Call November 05, 2019, 04:30 PM ET Company Participants Pete De Spain - VP, IR Troy Wilson - President & CEO Marc Grasso - CFO Antonio Gualberto - Chief Medical Officer & Head of Development Conference Call Part...

SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that an abstract related to the Company’s lead drug candidate, ti...

Image source: The Motley Fool. Kura Oncology, Inc.   (NASDAQ: KURA) Q3 2019 Earnings Call Nov 5, 2019 , 4:30 p.m. ET Operator Continue reading

Kura Oncology (NASDAQ: KURA ): Q3 GAAP EPS of -$0.36 beats by $0.02 . More news on: Kura Oncology, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

– Updated data from Phase 2 trial of tipifarnib in HRAS mutant HNSCC support enrichment strategy in ongoing registration-directed trial – – Data from Phase 2 trial of tipifarnib in AITL accepted for oral presentation at ASH 2019 – – Initiation of firs...

SAN DIEGO, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report third quarter 2019 financial results after the close...